CXCR4 and lip and oral cavity carcinoma: CXCR4 antagonist, AMD3100, decreases cell migration and cell invasion of oral cancers and inhibits lymph node metastasis in these cells due to the reduced migration of tumor cells by the suppression of the SDF-1/CXCR4 gradient and inhibition of lymphangiogenesis [9].